Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$1.11B |
| 2 |
Peloton Interactive
PTON
|
+$877M |
| 3 |
Coupang
CPNG
|
+$455M |
| 4 |
DoorDash
DASH
|
+$423M |
| 5 |
Spotify
SPOT
|
+$387M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$2.87B |
| 2 |
Tesla
TSLA
|
+$1.41B |
| 3 |
Moderna
MRNA
|
+$1.35B |
| 4 |
Amazon
AMZN
|
+$928M |
| 5 |
NetEase
NTES
|
+$766M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 27.57% |
| 2 | Healthcare | 26.02% |
| 3 | Technology | 18.64% |
| 4 | Communication Services | 12.04% |
| 5 | Financials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Bumble
BMBL
$373M
| $20M | 0.01% |
400,000
| – | – |
|
227
Health Catalyst
HCAT
$128M
| $19.1M | 0.01% |
381,003
+81,441
| +27% | +$4.44M |
|
228
Stratasys
SSYS
$774M
| $18.8M | 0.01% |
874,383
-13,969
| -2% | -$303K |
|
229
FirstCash
FCFS
$8.78B
| $18.8M | 0.01% |
214,587
-106,396
| -33% | -$8.8M |
|
230
Axogen
AXGN
$2.5B
| $18.4M | 0.01% |
1,161,659
-4,578
| -0.4% | -$82.2K |
|
231
Royal Caribbean
RCL
$85.6B
| $16.8M | 0.01% |
188,339
-87,860
| -32% | -$7.11M |
|
|
SIX
232
DELISTED
Six Flags Entertainment Corp.
SIX
| $16.4M | 0.01% |
385,701
-183,919
| -32% | -$7.64M |
|
233
Align Technology
ALGN
$12.3B
| $16.4M | 0.01% |
24,631
-2,723
| -10% | -$1.85M |
|
|
NBTX
234
Nanobiotix
NBTX
$1.94B
| $15.9M | 0.01% |
1,400,000
| – | – |
|
|
CLLS
235
Cellectis
CLLS
$285M
| $13.6M | 0.01% |
1,076,525
+42,653
| +4% | +$591K |
|
236
HUTCHMED
HCM
$2.17B
| $13.5M | 0.01% |
367,965
+707
| +0.2% | +$27.8K |
|
237
Ascendis Pharma A/S
ASND
$16.8B
| $13.3M | 0.01% |
83,434
+8,882
| +12% | +$1.22M |
|
238
Cooper Companies
COO
$14.5B
| $13M | 0.01% |
125,492
-6,916
| -5% | -$738K |
|
239
Sherwin-Williams
SHW
$89.8B
| $12.4M | 0.01% |
44,453
-2,933
| -6% | -$858K |
|
|
OCFT
240
DELISTED
OneConnect Financial Technology
OCFT
| $12.2M | 0.01% |
297,315
-705
| -0.2% | -$44.7K |
|
241
Visa
V
$677B
| $11.7M | 0.01% |
52,510
-3,340
| -6% | -$783K |
|
242
Burford Capital
BUR
$971M
| $11.3M | 0.01% |
1,038,109
+247,489
| +31% | +$2.75M |
|
243
Veeva Systems
VEEV
$37.4B
| $11.1M | 0.01% |
38,471
+4,188
| +12% | +$1.33M |
|
244
Spire Global
SPIR
$555M
| $10.9M | 0.01% |
+108,256
| New | +$9.12M |
|
|
KDNY
245
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $10.7M | 0.01% |
837,576
-1,804
| -0.2% | -$23.7K |
|
246
DT Midstream
DTM
$13.4B
| $10.6M | 0.01% |
+229,294
| New | +$10M |
|
|
BNFT
247
DELISTED
Benefitfocus, Inc.
BNFT
| $10.4M | 0.01% |
940,392
-4,014
| -0.4% | -$48.8K |
|
248
Ionis Pharmaceuticals
IONS
$9.4B
| $10.1M | 0.01% |
302,003
+30,607
| +11% | +$1.15M |
|
249
Verisk Analytics
VRSK
$25B
| $10.1M | 0.01% |
50,495
-3,768
| -7% | -$730K |
|
|
DCBO
250
Docebo
DCBO
$566M
| $9.89M | 0.01% |
135,418
+21,483
| +19% | +$1.58M |
|
Similar funds
Baillie Gifford & Co's Q3 2021 Portfolio in Review
As of Q3 2021, Baillie Gifford & Co held 509 positions worth $191B, down 6.8% from $205B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Baillie Gifford & Co's Q3 2021 filing shows 38 new, 113 increased, 204 reduced and 17 closed positions. Its largest new stake was Ginkgo Bioworks: 2,275,070 shares worth $1.05B. The largest sale was Alibaba, an estimated $2.87B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q3 2021 buy was Ginkgo Bioworks: 2,275,070 shares worth $1.05B.
- Baillie Gifford & Co added most to Peloton Interactive in Q3 2021, an estimated $877M increase.
- Baillie Gifford & Co's biggest Q3 2021 reduction was Alibaba, cutting an estimated $2.87B.
- Baillie Gifford & Co fully exited EOG Resources in Q3 2021, selling an estimated $329M.
- Baillie Gifford & Co's ten largest holdings make up 40% of its $191B portfolio in Q3 2021.
- Baillie Gifford & Co opened 38 new positions and closed 17 in Q3 2021.
- Baillie Gifford & Co's portfolio value fell 6.8% quarter-over-quarter to $191B.
Based on Baillie Gifford & Co's 13F filing for Q3 2021, filed 19 Oct 2021.